Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Yingcheng WuLifeng LinYanting ShenHuiqun WuPublished in: International journal of cancer (2018)